Epidemiologic factors associated with seropositivity to human papillomavirus type 16 and 18 virus-like particles and risk of subsequent infection in men

Cancer Epidemiology Biomarkers and Prevention

Volumn 19, Issue 2, 2010, Pages 511-516

  Lu, Beibei ^a,b   Hagensee, Michael E ^c   Lee, Ji Hyun ^a,b   Wu, Yougui ^b   Stockwell, Heather G ^b   Nielson, Carrie M ^d   Abrahamsen, Martha ^a   Papenfuss, Mary ^a   Harris, Robin B ^e   Giuliano, Anna R ^a,b  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

^c LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^e UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ARTICLE; ENZYME LINKED IMMUNOSORBENT ASSAY; EPIDEMIC; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMORAL IMMUNITY; INCIDENCE; INFECTION RISK; INNATE IMMUNITY; MAJOR CLINICAL STUDY; MALE; MALE GENITAL TRACT INFECTION; MALE HOMOSEXUAL; NONHUMAN; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; SMOKING; VIRUS LIKE AGENT;

ADOLESCENT; ADULT; ANTIBODIES, VIRAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; INCIDENCE; MALE; PAPILLOMAVIRUS INFECTIONS; RISK FACTORS; SEROEPIDEMIOLOGIC STUDIES; VIRION; YOUNG ADULT;

EID: 76149126430     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-09-0790     Document Type: Article

References (25)

1. Clifford GM, Shin HR, Oh JK, et al. Serologic response to oncogenic human papillomavirus types in male and female university students in Busan, South Korea. Cancer Epidemiol Biomarkers Prev 2007;16:1874-9.
2. Hagensee ME, Kiviat N, Critchlow CW, et al. Seroprevalence of human papillomavirus types 6 and 16 capsid antibodies in homosexual men. J Infect Dis 1997;176:625-31.
3. Kreimer AR, Alberg AJ, Viscidi R, Gillison ML. Gender differences in sexual biomarkers and behaviors associated with human papillomavirus-16, -18, and -33 seroprevalence. Sex Transm Dis 2004;31:247-56.
4. Marais D, Rose RC, Lane C, Aspinall S, Bos P, Williamson AL. Seroresponses to virus-like particles of human papillomavirus types 16, 18, 31, 33, and 45 in San people of Southern Africa. J Med Virol 2000;60:331-6.
5. Slavinsky J III, Kissinger P, Burger L, Boley A, DiCarlo RP, Hagensee ME. Seroepidemiology of low and high oncogenic risk types of human papillomavirus in a predominantly male cohort of STD clinic patients. Int J STD AIDS 2001;12:516-23.
6. Stone KM, Karem KL, Sternberg MR, et al. Seroprevalence of human papillomavirus type 16 infection in the United States. J Infect Dis 2002;186:1396-402.
7. Strickler HD, Kirk GD, Figueroa JP, et al. HPV 16 antibody prevalence in Jamaica and the United States reflects differences in cervical cancer rates. Int J Cancer 1999;80:339-44.
8. Svare EI, Kjaer SK, Nonnenmacher B, et al. Seroreactivity to human papillomavirus type 16 virus-like particles is lower in high-risk men than in high-risk women. J Infect Dis 1997;176:876-83.
9. Thompson DL, Douglas JM, Jr., Foster M, et al. Seroepidemiology of infection with human papillomavirus 16, in men and women attending sexually transmitted disease clinics in the United States. J Infect Dis 2004;190:1563-74.
10. Ho GY, Studentsov Y, Hall CB, et al. Risk factors for subsequent cervicovaginal human papillomavirus (HPV) infection and the protective role of antibodies to HPV-16 virus-like particles. J Infect Dis 2002;186:737-42.
11. Viscidi RP, Schiffman M, Hildesheim A, et al. Seroreactivity to human papillomavirus (HPV) types 16, 18, or 31 and risk of subsequent HPV infection: results from a population-based study in Costa Rica. Cancer Epidemiol Biomarkers Prev 2004;13:324-7.
12. Giuliano AR, Lu B, Nielson CM, et al. Age-specific prevalence, incidence, and duration of human papillomavirus infections in a cohort of 290 US men. J Infect Dis 2008;198:827-35.
13. Lu B, Wu Y, Nielson CM, et al. Factors associated with acquisition and clearance of human papillomavirus infection in a cohort of US Men: a prospective study. J Infect Dis 2009;199:362-71.
14. Gravitt PE, Peyton CL, Apple RJ, Wheeler CM. Genotyping of 27 human papillomavirus types by using L1 consensus PCR products by a single-hybridization, reverse line blot detection method. J Clin Microbiol 1998;36:3020-7.
15. Hagensee ME, Koutsky LA, Lee SK, et al. Detection of cervical antibodies to human papillomavirus type 16 (HPV-16) capsid antigens in relation to detection of HPV-16 DNA and cervical lesions. J Infect Dis 2000;181:1234-9.
16. Liang K-Y, Zeger SL. Longitudinal data analysis using generalized linear models. Biometrika 1986;73:13-22.
17. Rothman KJ, Greenland S. Modern Epidemiology. 2nd ed. Philadelphia (PA): Lippincott Williams & Wilkins; 1998.
18. Marais DJ, Constant D, Allan B, et al. Cervical human papillomavirus (HPV) infection and HPV type 16 antibodies in South African women. J Clin Microbiol 2008;46:732-9.
19. Nonnenmacher B, Pintos J, Bozzetti MC, et al. Epidemiologic correlates of antibody response to human papillomavirus among women at low risk of cervical cancer. Int J STD AIDS 2003;14:258-65.
20. Viscidi RP, Kotloff KL, Clayman B, Russ K, Shapiro S, Shah KV. Prevalence of antibodies to human papillomavirus (HPV) type 16 virus-like particles in relation to cervical HPV infection among college women. Clin Diagn Lab Immunol 1997;4:122-6.
21. Dunne EF, Nielson CM, Hagensee ME, et al. HPV 6/11, 16, 18 seroprevalencein men in two U.S. cities. Sex Transm Dis 2009;36:671-4.
22. Human papillomaviruses. IARC Monogr Eval Carcinog Risks Hum 2007;90:1-636.
23. D'Souza G, Agrawal Y, Halpern J, Bodison S, Gillison ML. Oral sexual behaviors associated with prevalent oral human papillomavirus infection. J Infect Dis 2009;199:1263-9.
24. de Pokomandy A, Rouleau D, Ghattas G, et al. Prevalence, clearance, and incidence of anal human papillomavirus infection in HIV-infected men: the HIPVIRG cohort study. J Infect Dis 2009;199:965-73.
25. Nyitray A, Smith D, Villa L, Ponce EL, Abrahamsen M, Giuliano A. High anal HPV prevalence in multinational samples: The HIM Study. Malmo (Sweden): The 25th International Papillomavirus Conference and Clinical Workshop; 2009.